Retinal Vein Occlusion

Overview of branch retinal vein occlusion and central retinal vein occlusion.

What is a Retinal Vein Occlusion?

Arteries bring blood to the eye and veins bring blood back to the heart. While arteries have tough walls which usually become harder with age, veins have thin walls which remain pliant and soft throughout life. Because of the anatomy of the eye, the retinal veins are prone to occlusion. There are two main locations where retinal veins are occluded. One is at the crossing of a retinal arteriole and branch retinal vein. An occlusion at a crossing of a branch retinal arteriole and branch retinal vein causes a branch retinal vein occlusion. The second is at the main trunk of the retinal vein where it leaves the eye through the optic nerve. An occlusion at the main trunk of the retinal vein causes a central retinal vein occlusion. The picture shows a photo with dilated veins and retinal hemorrhages from a fresh central retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The retinal veins dilate and their are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen. Monthly examinations of pateints with CRVO for less than six months are very important. Some patients with CRVO and very bad circulation, develop a severe type of glaucoma. In this situation, the eye becomes red and painful and without treatment, total visual loss can occur rapidly. If an examining doctor sees early signs that this complication may occur, then laser treatment can sometimes protect the eye. Once the pressure rise occurs, surgery can be helpful.

Read more

Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Retinal Vein Occlusion


The Pharmaceutical Journal

Bevacizumab as effective as aflibercept for central retinal vein occlusion
The Pharmaceutical Journal
Bevacizumab as effective as aflibercept for central retinal vein occlusion. Clinical Pharmacist1 JUN 2017. Off-label drug is as effective as standard treatment for macular oedema, according to randomised controlled trial. Retinal image showing macular ...


Clearside Biomedical's TANZANITE Extension Study in Patients with ...
GlobeNewswire (press release)
74% of RVO Patients Receiving CLS-TA for Suprachoroidal Administration Together with Intravitreally Administered EYLEA® Did Not Receive Any Additional ...

and more »

The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
Dove Medical Press
Methods: The study comprised an interventional prospective study of patients with macular edema due to central retinal vein occlusion (CRVO) or branch retinal vein occlusion, followed for 12 months. Treatment-naïve patients with reduced best-corrected ...


Medgadget (blog)

Pharmaceutical and Healthcare Latest Report : Retinal Vein Occlusion – Pipeline Review, H1 2017
Medgadget (blog)
“The Report Retinal Vein Occlusion – Pipeline Review, H1 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”. Global Markets Direct's latest ...

and more »

KL Daily

Regeneron (REGN) Stock on Fire: What's Behind the Surge?
Zacks.com
The drug is also approved for macular edema following retinal vein occlusion, which includes macular edema post central retinal vein occlusion as well as macular edema following branch retinal vein occlusion. Meanwhile, Regeneron is working on ...
SEC FORM 4 - SEC.govSEC.gov

all 107 news articles »

Research Briefs July 2017
P&T Community
A head-to-head comparison of two drugs widely used for macular edema due to central retinal vein occlusion—bevacizumab (Avastin, Genentech) and aflibercept (Eylea, Regeneron)—found that both drugs improved visual acuity similarly. But Eylea does it ...


Healio

Comparison of Ranibizumab and Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusions in Routine ...
Healio
Visual morbidity from retinal vein occlusion (RVO) is largely a result of the subsequent macular edema (ME). Pathophysiologic studies have shown markedly elevated vitreous levels of vascular endothelial growth factor (VEGF) in patients with RVO.


Medscape

Despite Significantly Different Pricing, Similar Efficacy for Key Anti-VEGF Agents in Macular Edema
Medscape
The goal of the multicenter clinical SCORE2 trial was to establish the safety and efficacy of bevacizumab compared with aflibercept in the treatment of macular edema secondary to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO).


WhaTech

New report examines the retinal vein occlusion drugs pipeline therapeutics review
WhaTech
Retinal Vein Occlusion Pipeline Review H1 2017 Pharmaceutical and Healthcare disease pipeline guide provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape. Retinal Vein Occlusion (Ophthalmology) pipeline guide also ...


Seeking Alpha

It's Time To Take Profits On Regeneron
Seeking Alpha
Eylea is a medicine approved for the treatment of patients with Wet Age-related Macular Degeneration (wetAMD), Macular Edema following Retinal Vein Occlusion (RVO) and Diabetic Macular Edema (DME). I'm a bit more pessimistic than consensus about ...


Will Regeneron's (REGN) Newly Approved Drugs Drive Growth ...
Nasdaq
We issued an updated report on Regeneron Pharmaceuticals, Inc. REGN on May 29. Regeneron's key growth driver, Eylea, continues to drive revenues..

and more »

Off-label use of medicine and medical malpractice: court finds ophthalmologist liable for vision loss
Lexology (registration)
The claimant, a 60-year old woman suffering from macular oedema due to retinal vein occlusion, underwent treatment by the defendant. This treatment included intraocular injections of the substance bevacizumab, sold under the tradename Avastin, ...


Eye jabs by nurses free up docs' time
The Straits Times
Two nurses have been trained so far, and they have given about 30 injections, under the supervision of doctors, to patients who have conditions such as wet age-related macular degeneration, diabetic maculopathy and retinal vein occlusions.


Eye injections now administered by nurses for eye diseases free up time for doctors at hospital
The Straits Times
SINGAPORE - Mr Han Boon Huat, 68, has to get an injection into his eye cavity every month at Tan Tock Seng Hospital (TTSH) to improve his age-related macular degeneration, an eye disease that blurs his vision. But unlike many other patients who get ...


Green Mountain Outlook

Retinal Vein Occlusion Pipeline Review H1 2017- Top Industry Intelligence, Major Key Players and Market Insights to ...
Green Mountain Outlook
Retinal Vein Occlusion Market Pipeline Review, H1 2017, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics. Retinal Vein Occlusion therapeutics ...


Motley Fool

How Regeneron Pharmaceuticals, Inc. Makes Most of Its Money ...
Motley Fool
Regeneron Pharmaceuticals (NASDAQ:REGN) has five drugs approved for sale by the Food and Drug Administration, but most of its revenue still comes from ...

and more »

Times of India

The heart's sight
Times of India
The heart plays a vital role in distributing blood to the various areas of the body including eyes. Symptoms of cardiovascular disease are not only present in the body, but also occur in the eyes. In fact, recent studies suggest a regular eye exam ...


Daily Astorian

Saving eyesight and sparing travel Latest eye care treatments come to the coast
Daily Astorian
One service we are particularly excited to be offering is intravitreal injections. This places medication directly into the eye for the treatment of wet, age-related macular degeneration, diabetic macular edema and macular edema following retinal vein ...


Policy Options (registration)

Empowering seniors through vision care
Policy Options (registration)
Significant progress has been made in the development of therapies and preventive treatments for eye diseases such as diabetic retinopathy, age-related macular degeneration, retinal vein occlusion and glaucoma. In many cases, vision can be preserved or ...


Market Realist

Regeneron Expected to Report Healthy Revenue Growth in 2017 ...
Market Realist
Regeneron Pharmaceuticals (REGN) is committed to maintaining leadership in the anti-VEGF market with its market-leading drug Eylea.

and more »

National Institutes of Health (press release)

Avastin as effective as Eylea for treating central retinal vein ... - NIH
National Institutes of Health (press release)
NIH-funded clinical trial shows use of either drug improved vision and had few side effects.

and more »

Bevacizumab On Par With Aflibercept in Retinal Vein Occlusion
MedPage Today
Bevacizumab (Avastin) had similar visual acuity outcomes to aflibercept (Eylea) in patients who had macular edema from central retinal vein or hemiretinal vein occlusion, researchers found. In the SCORE2 trial, mean visual acuity letter score (VALS) ...


Investor's Business Daily

Here's How Novartis Just Won Back The Edge In Ocular Therapy
Investing.com
It first picked up approval in a wet AMD indication back in 2006 and has since gone on to expand into retinal vein occlusion type AMD, diabetic macular edema (DME) and myopic choroidal neovascularization. Just this year, this expanded further into all ...
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week ...Novartis

all 32 news articles »

The Cancer Letter Publications

A nascent group of academics plans to conduct randomized trials to determine value of care
The Cancer Letter Publications
I think an interesting example of studies like that come from the field of ophthalmology, where in both macular degeneration and edema secondary to retinal vein occlusion, a dose of bevacizumab at $50 produces the same results as a dose of more ...


News-Medical.net

Central Retinal Vein Occlusion (CRVO) - News Medical
News-Medical.net
Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back ...
US, UK trials underway to compare treatments for CRVOHealio

all 3 news articles »

Science Daily

Surgical eye robot performs precision-injection in patient with retinal ...
Science Daily
Surgeons have operated on a patient with retinal vein occlusion using a surgical robot. Operated by an eye surgeon, the robot uses a needle of barely 0.03 ...
Highly Precise Eye Procedures Are Now Possible Thanks to This ...Wccftech

all 3 news articles »

WABI

Healthy Living: Retinal Vein Occlusion | WABI TV5
WABI
Healthy Living - November 15, 2016 Michael Johnson, MD, Retinal Surgeon - Eastern Maine Medical Center What Is Central Retinal Vein Occlusion (CRVO)?

and more »

Northeast Mississippi Daily Journal

Health briefs for June 23
Northeast Mississippi Daily Journal
Retina surgeon Dr. Heather Hancock will be the featured speaker. Dr. Hancock treats patients with macular degeneration, retinal detachment, vein or arterial occlusions, diabetic retinopathy and several other conditions, including pediatric retinal ...


Surgical robot successfully removes blood clot in patient with retinal vein occlusion
Healio
In a press release, the team of surgeons that carried out the operation called this technique of retinal vein cannulation (RVC) “a revolutionary treatment that addresses the cause of retinal vein occlusion by removing the blood clot in the retinal vein.”.


H1 Macular Edema Market Pipeline Review 2017 Trend Analysis ...
satPRnews (press release)
Macular Edema – Pipeline Review, H1 2017, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape. Request a sample of this report ...

and more »
» Load more